05 November 2026
2QFY27 Results Update | Sector: Healthcare

Rubicon Research

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	RUBICON IN
Equity Shares (m)	166
M.Cap.(INRb)/(USDb)	288.1 / 3
52-Week Range (INR)	1899 / 609
1, 6, 12 Rel. Per (%)	-1/78/171
12M Avg Val (INR M)	531

Financials & Valuations (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	17.5	23.0	27.6
EBITDA	4.0	5.6	6.9
Adjusted PAT	2.5	3.5	4.5
EBITDA Margin (%)	22.8	24.5	25.0
Cons. Adj EPS (INR)	14.9	21.5	27.5
EPS Growth (%)	83.6	43.7	28.1
BV/Share (INR)	78.1	97.2	121.4
Ratios			
Net D-E	-0.1	-0.1	-0.2
RoE (%)	27.0	24.5	25.2
RoCE (%)	26.6	28.0	30.0
Payout (%)	11.8	11.8	11.8
Valuations			
P/E (x)	116.4	81.0	63.3
EV/EBITDA (x)	71.7	50.7	41.2
Div. Yield (%)	0.1	0.1	0.2
FCF Yield (%)	-0.1	0.5	0.9
EV/Sales (x)	16.4	12.5	10.3

Shareholding Pattern (%)

As On	Sep-26	Jun-26	Sep-25
Promoter	51.2	59.8	60.0
DII	15.7	9.4	10.5
FII	9.0	7.5	9.4
Others	24.0	23.3	20.1

FII includes depository receipts

CMP: INR1,741 TP: INR2,090 (+20%) Buy

Beat streak continues; margin guidance raised again

Compliance track-record/R&D productivity underpin long-term earnings visibility

- Rubicon Research (Rubicon) has beaten our estimates yet again, extending its consistent, long streak of beats since its IPO in Oct'25. Revenue, EBITDA, and PAT stood 5%, 11%, and 7% ahead of our estimates, respectively. Sequential revenue scale-up was also strong following the tactical measures taken in 1QFY27, with the consequent operating leverage further lifting profitability for the quarter.
- 2QFY27 revenue grew 40% YoY and 8% QoQ. This was particularly noteworthy as growth was driven by stronger traction in already commercialized products, even as the commercialization of three products approved in 2QFY27 were deferred by a quarter (since revised norms require export license applications to be made after receipt of product approval). This is expected to bode well for growth ahead as these recently approved products get commercialized.
- Rubicon has raised its FY27 EBITDA margin guidance for the second straight quarter: from 22–23% in 4QFY26 to 23%+ in 1QFY27, and now to 24%+ in 2QFY27. This also bears testimony of management's track record of guiding conservatively and delivering ahead of expectations. Notably, the latest upgrade comes despite further opex expected from the operationalization of the Pithampur facility and likely further growth-enabler costs related to the Arinna prescription business.
- All of Rubicon's facilities have now completed USFDA inspections, with each site either classified NAI/VAI or expected to receive VAI. Every inspection except one at an R&D site was unannounced. NJ site was inspected in May'26 and EIR was received with VAI status. Pithampur site (Form 483 -2 observations) was inspected in Jul'26 and received regulatory filing approval in 1QFY27. Satara site inspection (Oct'26) had form 483 with one observation. Ambernath site inspection (Oct'26) resulted in form 483 with three observations related to system improvements and two related to product application review. All the observations of all the facilities are procedural in nature with no data integrity issues and, hence, are expected to result in a VAI status. This provides a strong testament to a robust and consistent compliance culture across the network.
- Pre-tax annualized RoACE remains remarkably strong at 36%, despite nearly 25% of capital employed (INR4b out of INR15.5b) being deployed in assets that are either pre-revenue or yet to materially contribute to returns.
- R&D productivity stands at 5.8x, based on annualized 1HFY27 revenue (ex-Arinna), against R&D spend over the preceding nine quarters (FY23, FY24 and 1QFY25). Notably, this INR2.2b of lagged spend supporting FY27 revenue is the lowest of the last three R&D cycles. Subsequent financial years will see benefit of materially higher lagged R&D spend cycles (INR2.8b for FY28, INR3.8b for FY29, and INR5b for FY30), which, combined with a proven track record of over 5x R&D productivity, provide strong growth visibility well into FY30.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com) | **Eshita Jain - Research Analyst** (Eshita.Jain@MotilalOswal.com)
Vipul Mehta - Research Analyst (vipul.mehta@motilaloswal.com) | **Khyati Sonthalia - Research Analyst** (khyati.sonthalia@motilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.
Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- We raise our FY27/FY28 earnings estimates by 4%/3%, factoring in faster scale-up of the existing portfolio and new launches. Rubicon brings together a rare combination of superior R&D productivity, strong execution, and a solid compliance culture. We reiterate our view that it offers the longest and strongest runway for earnings growth, not just within healthcare but across our coverage universe. We value Rubicon at 70x 12M forward earnings to arrive at a TP of INR2,090. Reiterate BUY.

Strong operating performance drives healthy earnings growth

- 2QFY27 revenue grew 40% YoY to INR5.8b (beat by 5%).
- Gross margins remained stable sequentially.
- EBITDA margin expanded 210bp YoY to 25% (beat by 140bp), supported by better operating leverage, with other expenses declining 310bp YoY as a percentage of sales.
- R&D expenses was 10.8% of sales (INR624m) for 2QFY27. R&D expenses are fully charged to the P&L.
- EBITDA increased 53% YoY to INR1.4b (beat by 11%).
- PAT surged 67.9% YoY to INR904m (beat by 7%).
- For 1HFY27, Revenue/EBITDA/PAT grew 45.3%/57.5%/80.3% to INR11.1b/INR2.7b/INR1.8b.

Highlights from the management commentary

- Rubicon received three product approvals in 2QFY27, with 90 active approved products as of Sep'26.
- In CC, revenue grew 23% YoY/5% QoQ to USD58m (Ex-Arinna) in 2QFY27.
- Specialty portfolio's contribution to gross profit for the quarter is 36%.
- Rubicon has raised its FY27 EBITDA margin guidance for the second straight quarter: from 22–23% in 4QFY26 to 23%+ in 1QFY27, and now to 24%+ in 2QFY27.
- Rubicon received three USFDA approval in 2QFY27. The commercialization was deferred by a quarter due to revised norms w.r.t export licenses. This makes the strong sequential revenue performance in 2QFY27 even more commendable.
- The company delivered strong profitability performance despite operative expense associated with three facilities (Pithampur, CSN and New Jersey), which are yet to contribute to revenue.
- Pithampur is expected to generate revenue from FY28 onwards. New Jersey commercialization is also expected in FY28 and is function of product filings, regulatory inspection and subsequent launches.

Quarterly Result Snapshot (INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27	
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			2Q	vs Est.
Gross Sales	**3,525**	**4,120**	**4,755**	**5,139**	**5,343**	**5,764**	**5,921**	**5,961**	**17,540**	**22,989**	**5,515**	**5%**
YoY Change (%)	11.3	39.2	51.7	43.5	51.6	39.9	24.5	16.0	36.6	31.1	33.8	
EBITDA	**791**	**943**	**1,081**	**1,187**	**1,291**	**1,441**	**1,451**	**1,460**	**4,002**	**5,643**	**1,301**	**11%**
YoY Change (%)	31.4	52.9	54.7	63.8	63.2	52.8	34.2	23.0	**51.5**	41.0	**38**	
Margins (%)	22.4	22.9	22.7	23.1	24.2	25.0	24.5	24.5	22.8	24.5	23.6	
Depreciation	96	119	116	123	151	180	182	183	453	698	159	
Interest	106	114	98	104	93	114	112	113	422	432	91	
Other Income	6	7	38	26	21	23	22	21	77	87	55	
PBT	**596**	**717**	**906**	**987**	**1,104**	**1,169**	**1,179**	**1,185**	**3,205**	**4,637**	**1,106**	
Tax	163	179	178	219	256	265	271	273	738	1,064	259	
Rate (%)	27.3	24.9	19.6	22.2	23.2	22.7	23.0	23.0	23.0	23.0	23.4	
Reported PAT	**433**	**539**	**728**	**768**	**848**	**904**	**908**	**912**	**2,467**	**3,572**	**848**	
Adj PAT	**433**	**539**	**728**	**768**	**820**	**904**	**908**	**912**	**2,467**	**3,544**	**848**	**7%**
YoY Change (%)	69.4	56.2	91.2	111.8	89.4	67.9	24.7	18.8	83.6	43.7	57.4	
Margins (%)	12.3	13.1	15.3	14.9	15.4	15.7	15.3	15.3	14.1	15.4	15.4	
EPS (INR)	**2.6**	**3.3**	**4.4**	**4.7**	**5.0**	**5.5**	**5.5**	**5.5**	**14.9**	**21.5**	**5.1**	**7%**

Highlights from the management commentary

- Pre-tax RoACE remains remarkably strong at 36% despite nearly 25% of capital employed (INR4b out of INR15.5b) being deployed in assets that are either pre-revenue or yet to materially contribute to returns.
- 2QFY27 financials include Arinna consolidation, contributing INR194m to revenue. However, Arinna's EBITDA contribution remained immaterial in 1HFY27.
- Net working capital improved to 117 days as of Sep'26 from 126 days in the previous FY, primarily due to quarterly fluctuations. Management expects working capital to normalize at 125–130 days.
- R&D productivity is driven by both revenue per molecule as well as higher number of products being launched. Moreover, the approach for R&D spend is portfolio-based rather than working on select high-value products.

Robust revenue growth and healthy pipeline support sustained momentum

- Rubicon reported 1HFY27 revenue growth of 45.3% YoY to INR11.1b, with 2QFY27 revenue increasing 39.9% YoY to INR5.8b. In CC terms, revenue rose over 5% QoQ to USD58m in 2Q, following tactical portfolio optimization in 1Q.
- Pricing remained stable, supported by the differentiated product portfolio. Top five products contributed 37% of 2Q revenue, compared with 39% in each of the preceding two quarters, indicating a gradual reduction in product concentration.
- The company received six product approvals in 1HFY27, taking its active approved portfolio to 90 products, of which 76 have been commercialized. Recent approvals are expected to support launches over the coming quarters.
- Specialty products contributed 36% of 1HFY27 gross profit, reflecting the increasing contribution from differentiated products.
- R&D expenditure stood at INR1.2b, or 10.8% of 1HFY27 revenue. Rubicon remains on track to invest over INR5b during FY26-1QFY28, with R&D productivity at 5.8x on an annualized FY27 basis, excluding Arinna.
- We expect Rubicon to deliver ~25% revenue CAGR over FY26-28, driven by the commercialization of recently approved products, scaling up of the differentiated and specialty portfolio, and ramp-up of capacities at Pithampur and New Jersey. Continued R&D investments and Arinna's expansion in India CNS formulations provide additional growth levers.

Strong return ratios despite 25% of the capital employed yet to generate meaningful revenue

- Rubicon has invested ~INR4b across pre-revenue manufacturing facilities and Arinna, including INR1.6b for acquiring Pithampur facility, INR349m in CSN, INR291m in New Jersey and INR1.74b in acquiring Arinna Lifesciences.
- Pithampur completed its USFDA inspection in Jul'26, with two procedural observations. Rubicon received regulatory filing approval in 1QFY27 and is implementing effort to scale-up commercial production from this facility.
- The New Jersey facility, acquired in Jul'26, is USFDA-inspected (EIR received with VAI status), Rubicon is in the process of filing products from this site.
- Arinna expands Rubicon's presence in the India CNS formulations market through a portfolio of 60 brands, three sales divisions and a field force of around 160 representatives.
- While investments form part of the INR15.5b capital employed, these assets are yet to generate meaningful revenue. Despite this, pre-tax RoACE stands strong at 36% on an annualized basis.

Reiterate BUY

- We raise our FY27/FY28 earnings estimates by 4%/3%, factoring in faster scale-up of the existing portfolio and new launches. Rubicon brings together a rare combination of superior R&D productivity, strong execution, and a solid compliance culture.
- We reiterate our view that it offers the longest and strongest runway for earnings growth, not just within healthcare but across our coverage universe. We value Rubicon at 70x 12M forward earnings to arrive at a TP of INR2,090. Reiterate BUY.


Exhibit 1: Rubicon has maintained health regulatory record across its facilities

Facility	Month of Inspection	Nature of Inspection	Outcome	Remarks
R&D – Canada	Apr-26	Unannounced	❖ Zero Observations	❖ EIR Received
R&D – Thane	Mar-25	Announced	❖ Zero Observations	❖ EIR Received
Manufacturing – Ambernath	Oct-26	Unannounced	❖ Three observations with respect to system improvement and two observations with respect to product application under review were issued, all five of which are procedural in nature and do not relate to data integrity	❖ Company working closely with the regulator to successfully conclude the evaluation in a timely manner
Manufacturing – Satara	Oct-26	Unannounced	❖ One observation, procedural in nature and does not relate to data integrity	❖ Response submitted in Oct-26. EIR awaited
Manufacturing – Pithampur	Jul-26	Unannounced	❖ Two observations, procedural in nature and do not relate to data integrity	❖ Response submitted in Jul-26. EIR awaited
Manufacturing – New Jersey, USA	May-26	Prior to acquisition	❖ Six observations during inspection under previous owner just about a month before acquisition	❖ EIR Received with VAI status

Source: MOFSL, Company


Story in charts

Exhibit 2: Three products approved in 2QFY27; commercialization rate at 84%




Source: MOFSL, Company

Exhibit 3: The share of specialty products in gross margin expanded 380bp over FY26




Source: MOFSL, Company

Exhibit 4: Revenue to post ~25% CAGR over FY26-28




Source: MOFSL, Company

Exhibit 5: Gross margin to gradually recover by FY28




Source: MOFSL, Company

Exhibit 6: Expect EBITDA CAGR of 31% over FY26-28



Source: MOFSL, Company

Exhibit 7: RoCE to improve with better utilization of assets



Source: MOFSL, Company

Financials and valuations

Income statement

Y/E March	FY23	FY24	FY25	FY26	FY27E	FY28E
Net sales	**3,935**	**8,539**	**12,843**	**17,540**	**22,989**	**27,622**
Change (%)	25.5	117.0	50.4	36.6	31.1	20.2
Total Expenditure	**3,750**	**6,993**	**10,200**	**13,537**	**17,346**	**20,726**
% of Sales	95.3	81.9	79.4	77.2	75.5	75.0
EBITDA	**185**	**1,546**	**2,643**	**4,002**	**5,643**	**6,896**
Margin (%)	4.7	18.1	20.6	22.8	24.5	25.0
Depreciation	361	390	366	453	698	776
EBIT	**-176**	**1,156**	**2,277**	**3,550**	**4,945**	**6,120**
Int. and Finance Charges	190	313	368	422	432	407
Other Income	255	185	36	77	87	152
PBT bef. EO Exp.	**-110**	**1,029**	**1,945**	**3,205**	**4,601**	**5,865**
EO Items	0	0	0	0	-36	0
PBT after EO Exp.	**-110**	**1,029**	**1,945**	**3,205**	**4,637**	**5,865**
Tax Rate (%)	-52.8	11.5	30.9	23.0	23.0	22.6
Reported PAT	**-169**	**911**	**1,344**	**2,467**	**3,572**	**4,540**
Adjusted PAT	**-169**	**911**	**1,344**	**2,467**	**3,544**	**4,540**
Change (%)	NA	NA	47.6	83.6	43.7	28.1
Margin (%)	-4.3	10.7	10.5	14.1	15.4	16.4

Balance Sheet

Y/E March	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	51	152	154	165	165	165
Total Reserves	2,813	3,698	5,256	12,723	15,876	19,882
Net Worth	**2,864**	**3,850**	**5,410**	**12,888**	**16,041**	**20,047**
Total Loans	3,197	4,245	4,176	3,110	2,310	2,210
Deferred Tax Liabilities	15	-9	-18	-130	-130	-130
Capital Employed	**6,075**	**8,086**	**9,568**	**15,868**	**18,221**	**22,127**
Gross Block	3,568	4,404	4,924	7,364	8,539	9,725
Less: Accum. Deprn.	1,596	1,845	2,131	2,583	3,281	4,057
Net Fixed Assets	**1,972**	**2,559**	**2,793**	**4,781**	**5,258**	**5,668**
Goodwill on Consolidation	22	513	476	539	539	539
Capital WIP	245	97	69	406	483	580
Total Investments	**77**	**80**	**74**	**358**	**358**	**358**
Curr. Assets, Loans&Adv.	**5,181**	**7,837**	**11,084**	**17,054**	**20,950**	**26,160**
Inventory	1,672	3,005	5,216	7,290	9,636	11,654
Account Receivables	2,250	3,015	3,238	5,087	6,487	7,568
Cash and Bank Balance	589	584	1,162	3,460	3,231	5,022
Loans and Advances	670	1,233	1,468	1,217	1,595	1,916
Curr. Liability & Prov.	**1,422**	**3,000**	**4,928**	**7,269**	**9,367**	**11,179**
Account Payables	969	1,767	2,391	3,775	4,787	5,676
Other Current Liabilities	282	660	1,122	1,016	1,331	1,599
Provisions	171	573	1,415	2,479	3,249	3,904
Net Current Assets	**3,759**	**4,837**	**6,156**	**9,785**	**11,583**	**14,982**
Appl. of Funds	**6,075**	**8,086**	**9,568**	**15,868**	**18,221**	**22,127**

Financials and valuations

Ratios

Y/E March	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)						
EPS	**-1.0**	**5.5**	**8.1**	**14.9**	**21.5**	**27.5**
Cash EPS	1.3	8.5	11.1	17.7	25.7	32.2
BV/Share	18.8	25.3	35.1	78.1	97.2	121.4
DPS	0.0	0.0	0.0	1.5	2.2	2.7
Payout (%)	0.0	0.0	0.0	11.8	11.8	11.8
Valuation (x)						
P/E	-1,701.0	315.5	213.8	116.4	81.0	63.3
EV/Sales	23.1	31.4	21.1	16.4	12.5	10.3
EV/EBITDA	491.2	173.6	102.6	71.7	50.7	41.2
Return Ratios (%)						
RoE	-5.7	27.1	29.0	27.0	24.5	25.2
RoCE	2.5	18.3	20.1	26.6	28.0	30.0
RoIC	-5.7	16.4	20.2	27.5	29.5	31.2
Working Capital Ratios						
Fixed Asset Turnover (x)	1.1	1.9	2.6	2.4	2.7	2.8
Asset Turnover (x)	0.6	1.1	1.3	1.1	1.3	1.2
Inventory (Days)	155	128	148	152	153	154
Debtor (Days)	209	129	92	106	103	100
Creditor (Days)	90	76	68	79	76	75
Leverage Ratio (x)						
Current Ratio	3.6	2.6	2.2	2.3	2.2	2.3
Interest Cover Ratio	-0.9	3.7	6.2	8.4	11.5	15.0
Net Debt/Equity	0.9	0.9	0.5	-0.1	-0.1	-0.2

Cash Flow statement

Y/E March	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	-110	1,029	1,945	3,205	4,637	5,865
Depreciation	361	390	366	453	698	776
Interest & Finance Charges	190	313	368	422	432	407
Direct Taxes Paid	-18	-181	-387	-1,085	-1,064	-1,325
(Inc)/Dec in WC	-1,081	-1,351	-900	-1,146	-2,027	-1,608
CF from Operations	**-660**	**199**	**1,391**	**1,849**	**2,674**	**4,115**
Others	-88	11	200	202	-87	-152
CF from Operating incl EO	**-747**	**210**	**1,592**	**2,050**	**2,588**	**3,963**
(Inc)/Dec in FA	-444	-560	-678	-2,289	-1,252	-1,284
Free Cash Flow	**-1,192**	**-350**	**914**	**-238**	**1,336**	**2,679**
(Pur)/Sale of Investments	0	0	0	0	0	0
CF from Investments	**-338**	**-685**	**-648**	**-4,097**	**-1,165**	**-1,132**
Issue of Shares	0	0	81	4,832	0	0
Inc/(Dec) in Debt	1,405	736	-148	-1,633	-800	-100
Interest Paid	-174	-298	-328	-365	-432	-407
CF from Fin. Activity	**1,228**	**436**	**-398**	**2,831**	**-1,651**	**-1,040**
Inc/Dec of Cash	**142**	**-40**	**545**	**784**	**-229**	**1,791**
Opening Balance	526	589	584	1,163	3,460	3,231
Closing Balance	**589**	**584**	**1,163**	**3,460**	**3,231**	**5,022**

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	**Expected return (over 12-month)**
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
   MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
   Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
   MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
   MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
   MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN .: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.